PF 3392455
Alternative Names: PF-3392455Latest Information Update: 07 Mar 2008
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 28 Feb 2008 Discontinued - Phase-I for Hypertension in USA (unspecified route)
- 31 Jul 2007 Phase I trials in Hypertension in USA (unspecified route)